Business
Outlook Therapeutics Announces Pricing of $5.0 Million Public Offering
ISELIN, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of
About this update from Outlook Therapeutics, Inc.
[{"type":"text","content":"ISELIN, N.J., March 24, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced the pricing of its previously announced public offering of 20,000,000 shares of its common stock and accompanying warrants to purchase up to an aggregate of 20,000,000 shares of common stock. Each share of common stock and accompanying common warrant are being sold together at a combined public offering price of $0.25. The aggregate gross proceeds of the offering are expected to be $5.0 million, before deducting placement agent fees and other offering expenses. Each common warrant will have an exercise price of $0.25 per share, will be exercisable immediately and will expire five years from the date of issuance. The offering is expected to close on or about March 25, 2026, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. Outlook Therapeutics intends to use the net proceeds from the offering primarily for working capital and general corporate purposes. The securities described above are being offered by Outlook Therapeutics pursuant to a “shelf” registration statement on Form S-3 (File No. 333-278340) that was originally filed with the Securities and Exchange Commission (the “SEC”) on March 28, 2024, and became effective on April 5, 2024. The public offering is being made only by means of a prospectus supplement and an accompanying prospectus that form a part of the effective registration statement. A preliminary prospectus supplement and an accompanying prospectus related to the public offering have been filed with the SEC. A final prospectus supplement and an accompanying prospectus will be filed with the SEC and will be available on the SEC’s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the public offering may also be obtained, when available, by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at [email protected]. This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be a...